Please correct me if I’m wrong but I don’t recall ‘primary efficacy endpoint’ being mentioned in conjunction with the interim futility analysis in the past. If so that’s a pretty big development. It may just be me and a hazy memory due to lack of coffee.
Ann: Circulation Research Highlights MSB Heart Failure Therapy, page-12
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.040(3.16%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.28 | $1.32 | $1.26 | $3.433M | 2.652M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39558 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 21776 | 3 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |